MOONLAKE IMMUNOTHERAPEUTICS Payments to Acquire Debt Securities, Available-for-sale
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) reported Payments to Acquire Debt Securities, Available-for-sale of $117.82 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-10
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $58.75M, a 50.07% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $59.07M, a 33.29% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $59.17M, a 59.74% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for fiscal 2025 was $265.37M, a 24.24% decline from fiscal 2024.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for fiscal 2024 was $350.28M, a 99.32% increase from fiscal 2023.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for fiscal 2023 was $175.73M, a 316.17% increase from fiscal 2022.
- MOONLAKE IMMUNOTHERAPEUTICS payments to acquire debt securities, available-for-sale for fiscal 2022 was $42.23M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 3 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 6 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 9 month as first filed | Payments to Acquire Debt Securities, Available-for-sale 10 month | Payments to Acquire Debt Securities, Available-for-sale 12 month | Payments to Acquire Debt Securities, Available-for-sale 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $58.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $117.82M 10-Q · filed 2026-08-10 | $176.98M derived: sum of 3 quarters · filed 2026-08-10 | $176.98M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2026-03-31 | $59.07M 10-Q · filed 2026-05-11 | $118.23M derived: sum of 2 quarters · filed 2026-05-11 | $118.23M derived: sum of 3 quarters · filed 2026-05-11 | $235.89M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-12-31 | $59.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $59.17M derived: sum of 2 quarters · filed 2026-02-25 | $176.83M derived: sum of 3 quarters · filed 2026-08-10 | $265.37M 10-K · filed 2026-02-25 | |||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $117.66M derived: sum of 2 quarters · filed 2026-08-10 | $206.21M 10-Q · filed 2025-11-05 | $353.15M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-06-30 | $117.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $206.21M 10-Q · filed 2026-08-10 | $353.15M derived: sum of 3 quarters · filed 2026-08-10 | $382.33M derived: sum of 4 quarters · filed 2026-08-10 | |||||
| 2025-03-31 | $88.55M 10-Q · filed 2026-05-11 | $235.49M derived: sum of 2 quarters · filed 2026-05-11 | $264.67M derived: sum of 3 quarters · filed 2026-05-11 | $351.11M derived: sum of 4 quarters · filed 2026-05-11 | |||||
| 2024-12-31 | $146.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $176.12M derived: sum of 2 quarters · filed 2026-02-25 | $262.57M derived: sum of 3 quarters · filed 2026-02-25 | $350.28M 10-K · filed 2026-02-25 | $350.28M 10-K · filed 2025-02-26 | ||||
| 2024-09-30 | $29.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $115.62M derived: sum of 2 quarters · filed 2025-11-05 | $203.34M 10-Q · filed 2025-11-05 | $203.33M 10-Q · filed 2024-11-07 | $203.34M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $86.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $174.16M 10-Q · filed 2025-08-05 | $174.15M 10-Q · filed 2024-08-07 | $174.16M derived: sum of 3 quarters · filed 2026-02-25 | $349.89M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $87.71M 10-Q · filed 2025-05-12 | $87.71M 10-Q · filed 2024-05-07 | $87.71M derived: sum of 2 quarters · filed 2026-02-25 | $263.45M derived: sum of 3 quarters · filed 2026-02-25 | $263.45M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $289.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $175.73M derived: sum of 2 quarters · filed 2026-02-25 | $175.73M derived: sum of 3 quarters · filed 2026-02-25 | $175.73M 10-K · filed 2026-02-25 | $175.73M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | $175.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $175.73M derived: sum of 2 quarters · filed 2024-11-07 | $175.73M 10-Q · filed 2024-11-07 | $175.73M derived: sum of 4 quarters · filed 2025-02-26 | |||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | -$1.00 derived: sum of 3 quarters · filed 2025-02-26 | ||||||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | -$1.00 derived: sum of 2 quarters · filed 2025-02-26 | |||||||
| 2022-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $42.23M 10-K · filed 2025-02-26 | |||||||
| 2022-09-30 | $42.23M 10-Q · filed 2023-11-14 | ||||||||
| 2021-12-31 | $0.00 10-K · filed 2023-03-20 | ||||||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |